Daniel Margolis, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Promaxo
    Topic: 
    ad-hoc consulting
    Date added: 
    05/21/2023
    Relationship end date: 
    05/21/2023
Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond